期刊
CIRCULATION RESEARCH
卷 102, 期 11, 页码 1319-1330出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCRESAHA.108.175943
关键词
angiogenesis; diabetes; stem cells
资金
- NHLBI NIH HHS [R01 HL065577-01, R01 HL065577-02, R01 HL065577-05, R01 HL065577-06, R01 HL065577-04, R01 HL065577-03, R01 HL065577, R01 HL065577-07] Funding Source: Medline
- NIA NIH HHS [P01 AG023071-010002, R01 AG026107-02, P01 AG023071-030002, P01 AG023071-040002, R01 AG026107-04, R01 AG026107-03, P01 AG023071, P01 AG023071-050002, P01 AG023071-020002, R01 AG026107-01A1, R01 AG026107] Funding Source: Medline
Cell therapy is a promising option for treating ischemic diseases and heart failure. Adult stem and progenitor cells from various sources have experimentally been shown to augment the functional recovery after ischemia, and clinical trials have confirmed that autologous cell therapy using bone marrow-derived or circulating blood-derived progenitor cells is safe and provides beneficial effects. However, aging and risk factors for coronary artery disease affect the functional activity of the endogenous stem/progenitor cell pools, thereby at least partially limiting the therapeutic potential of the applied cells. In addition, age and disease affect the tissue environment, in which the cells are infused or injected. The present review article will summarize current evidence for cell impairment during aging and disease but also discuss novel approaches how to reverse the dysfunction of cells or to refresh the target tissue. Pretreatment of cells or the target tissue by small molecules, polymers, growth factors, or a combination thereof may provide useful approaches for enhancement of cell therapy for cardiovascular diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据